A practical reference on G protein-coupled receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-02. Anything still debated is marked as such rather than presented as settled.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Grouchy organised a successful and well-ordered retreat towards Paris, where Marshal Davout had 117,000 men ready to turn back the 116,000 men of Blücher and Wellington. General Vandamme was defeated at the Battle of Issy and negotiations for surrender had begun.
== Function == The protein encoded by this gene is an adaptor protein which contains five LIM domains, or double zinc fingers. The protein is likely involved in integrin signaling through its LIM domain-mediated interaction with integrin-linked kinase, found in focal adhesion plaques. It is also thought to act as a bridge linking integrin-linked kinase to NCK adaptor protein 2, which is involved in growth factor receptor kinase signaling pathways. Its localization to the periphery of spreading cells also suggests that this protein may play a role in integrin-mediated cell adhesion or spreading.
5-HT2C receptor agonists are a class of drugs that activate 5-HT2C receptors. They have been investigated for the treatment of a number of conditions including obesity, psychiatric disorders, sexual dysfunction and urinary incontinence. The 5-HT2C receptors are one of three subtypes that belong to the serotonin 5-HT2 receptor subfamily along with 5-HT2A and 5-HT2B receptors. The development of 5-HT2C agonists has been a major obstacle, because of severe side effects due to a lack of selectivity. Activation of 5-HT2A receptors can induce hallucinations, and the activation of 5-HT2B receptors has been implicated in cardiac valvular insufficiency and possibly in pulmonary hypertension.
Sources: en.wikipedia.org
==== Air via nasogastric tube ==== Several neonatologists have described the allegation that Letby murdered three infants by injecting air into their stomachs via a nasogastric tube as implausible, variously calling the theory "nonsensical", "ridiculous", "fantastical" and "not practically feasible". An X-ray heavily relied upon by the prosecution in relation to Child C was taken when Letby had not been on shift since the infant's birth. Following the trial, the prosecution's lead medical witness, Dr Dewi Evans, subsequently stated that he had changed his opinion regarding the cause of Baby C's death. He no longer believed that the air in Baby C's stomach, which he had told the jury had caused the infant's collapse, was responsible for his death. Instead, Evans said that the stomach bubble was not responsible for the death and that Baby C died later, as a result of air entering the bloodstream. He therefore altered his view of the precise physiological mechanism by which Baby C died, while continuing to maintain that Letby was responsible for Baby C's death. The Lee panel concluded that there was no evidence that air had been forced down any infant's nasogastric tube.
== See also == Syndrome of inappropriate antidiuretic hormone secretion (SIADH) Oxytocin Vasopressin receptor Vasopressin receptor antagonists Copeptin Anterior pituitary Hypothalamus Atrial natriuretic peptide: When the atrium stretches, blood pressure is considered to be increased and sodium is excreted to lower blood pressure. Renin-angiotensin system: When the blood flow through the juxtaglomerular apparatus decreases, blood pressure is considered low, and the adrenal cortex secretes aldosterone to increase sodium reabsorption in the collecting duct, thereby increasing blood pressure. Bainbridge reflex: In response to stretching of the right atrium wall, heart rate increases, lowering venous blood pressure. Baroreflex: When the stretch receptors in the aortic arch and carotid sinus increase, the blood pressure is considered to be elevated and the heart rate decreases to lower blood pressure.
On 4 November, Chinese Foreign Ministry spokeswoman Mao Ning defended China's growing cooperation with Venezuela, saying it "constitutes normal cooperation between sovereign states" and is "not directed against any third party". She was quoted as saying "China supports strengthened international cooperation to combat transnational crime and opposes the use or threat of force in international relations." She added that China "opposes any attempt to undermine peace and stability in Latin America and the Caribbean, as well as unilateral coercive actions against foreign vessels that exceed reasonable and necessary limits." China urged the US to "carry out regular judicial and law enforcement cooperation through bilateral and multilateral legal frameworks". The Iranian ambassador to the UN in Geneva condemned the attack as illegal under international law. Journalist Katy Balls wrote that the strikes were "a response to Beijing's fast-growing influence in Latin America." In November 2025, Pope Leo XIV noted that the strikes were gradually nearing Venezuela's coastline and stated that they were only "increasing tension"; he called for the United States and Venezuela to "seek dialogue".
Sources: en.wikipedia.org
5 April COVID-19 pandemic: Preclinical data for a new vaccine developed at the Medical University of Vienna indicates it is effective against all SARS-CoV-2 variants known to date, including Omicron. A study presents a mechanism by which the hypothesized potential dark-energy-explaining quintessence, if true, would smoothly cause the accelerating expansion of the Universe to inverse to contraction, possibly within the cosmic near-future (100 My) given current data. It concludes that its end-time scenario theory fits "naturally with cyclic cosmologies [(each a theory of cycles of universe originations and ends, rather than the theories of one Big Bang beginning of the Universe/multiverse, to which authors were major contributors)] and recent conjectures about quantum gravity".
Development chamber preparation: The development solvent or solvent mixture is placed into a transparent container (separation/development chamber) to a depth of less than 1 centimetre. A strip of filter paper (aka "wick") is also placed along the container wall. This filter paper should touch the solvent and almost reach the top of the container. The container is covered with a lid and the solvent vapors are allowed to saturate the atmosphere of the container. Failure to do so results in poor separation and non-reproducible results. Development: The TLC plate is placed in the container such that the sample spot(s) are not submerged into the mobile phase. The container is covered to prevent solvent evaporation. The solvent migrates up the plate by capillary action, meets the sample mixture, and carries it up the plate (elutes the sample). The plate is removed from the container before the solvent reaches the top of the plate; otherwise, the results will be misleading. The solvent front, the highest mark the solvent has travelled along the plate, is marked. Visualization: The solvent evaporates from the plate. Visualization methods include UV light, staining, and many more.
Since the 1920s, pedoscopes have been installed in many shoe stores in North America and Europe, more than 10,000 in the U.S. alone, following the invention of Jacob Lowe, a Boston physicist. They were X-ray machines used to check the fit of shoes and to promote sales, especially to children. Children were particularly fascinated by the sight of their footbones. X-rays were often taken several times daily to evaluate the fit of different shoes. Most were available in shoe stores until the early 1970s. The energy dose absorbed by the customer was up to 116 rads, or 1.16 grays. In the 1950s, when medical knowledge of the health risks was already available, pedoscopes came with warnings that shoe-buyers should not be scanned more than three times a day and twelve times a year. By the early 1950s, several professional organizations issued warnings against the continued use of shoe-mounted fluoroscopes, including the American Conference of Governmental Industrial Hygienists, the American College of Surgeons, the New York Academy of Medicine, and the American College of Radiology. At the same time, the District of Columbia enacted regulations requiring that shoe-mounted fluoroscopes be operated only by a licensed physical therapist. A few years later, the state of Massachusetts passed regulations stating that these machines could only be operated by a licensed physician. In 1957, the use of shoe-mounted fluoroscopes was banned by court order in Pennsylvania.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.